echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Several drugs used to treat the new crown pneumonia were red-lighted.

    Several drugs used to treat the new crown pneumonia were red-lighted.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At present, the number of newly diagnosed cases worldwide is approaching 3 million, the number of deaths exceeds 200,000, and the number is growing.
    at the same time, the expected "special effects drug" still does not appear, previously high hopes of a number of drugs recently exposed a number of problems, the more obvious aspect is the drug safety problem.
    including "people's hope" Redsewe, hydroxychloroquine, chloroquine phosphate and other drugs, including a certain drug safety problems, let us look at the specific situation.
    . Redsewe fell to the "god", a distance from "special effects" In many new crown pneumonia chemicals, Gilead's scientific development of Redsewe was highly anticipated, known as "the people's hope."
    but recent research has revealed that Redsewey has fallen from the altar, at least as far away as the "special effects" that people expect.
    , the highest attention should be the recent results of a recent clinical trial in China that were unexpectedly disclosed by the WHO in advance, showing no significant improvement.
    followed by a clinical study of 53 people published in the New England Journal of Medicine, which showed that only 36 people (68%) had improved symptoms, while 12 (23%) had severe side effects, including polyorgan dysfunction syndrome, septic shock and acute kidney injury and hypertension.
    in addition, our researchers recently published a study on biorxiv entitled A preliminary study on the health of the health-toxic of GS-5734 on male mice, which showed that the sperm of mice deteriorated significantly as the redssevir dose increased;
    concluded that high doses of Redseve (GS-5734) can cause testicular toxicity in mice, leading to a decrease in sperm parameters.
    .S. The combination of hydroxychloroquine and azithromycin has been shown to cause heart disease to become a combination of hydroxychloroquine (antimalarial drugs) and azithromycin (antibiotics) and has previously been shown to have some efficacy for neo-coronapneumonia.
    However, a recent study published in the international authoritative journal Nature Medicine confirmed that the combination of therapies significantly increased the risk of different types of heart rhythm abnormalities, including prolonged QT inter-periods, drug-induced cutting-edge torsional chamber velocity, and sudden cardiac death.
    in the study, the researchers found that most patients with new coronary pneumonia treated with hydroxychloroquine and azithromycin experienced an extended period of QT, which may have been exacerbated by COVID-19 and other underlying diseases.
    , the researchers note that the condition of this group of patients should be continuously monitored during treatment, especially those with other diseases and those receiving other therapeutic drugs that lead to prolonged QT duration.
    Wednesday. High doses of chloroquine are harmful to severe neo-coronal pneumonia Recently, JAMA Network Open, a sub-journal of the Journal of the American Medical Association, published data from a randomized controlled clinical trial showing that high doses of chloroquine treatment for COVID-19 is harmful to patients and leads to more arrhythmia and does not improve patient mortality.
    the clinical trial had a sample size of 440 people who were terminated after 81 patients were enrolled due to severe adverse events.
    the results of the study showed that high-dose medication did not benefit patients on the most important survival indicators.
    14 days of treatment, the mortality rate was higher in the high-dose group (39 per cent in the high-dose group and 15 per cent in the low-dose group).
    , there were more safety problems in the high-dose group, including more hyperlytic kinase increases in the high-dose group, more arrhythmia, tachycardia, and longer QTc intervals.
    conclusion In addition to the above drugs, many new coronary pneumonia drugs actually have certain adverse reactions, such as: a) Abidol have adverse digestive tract reactions; Other adverse reactions such as platelet reduction, reduced neutrophil and white blood cell count, and decreased hemoglobin, d) lopina/Litonevir have adverse reactions such as fetal abnormalities (28%), gastrointestinal system damage (15%), systemic damage (14%), liver and bile system damage (9%), metabolic and nutritional disorders (9%).
    China attaches importance to the safety of drugs at the beginning of the use of new crown drugs, such as the Chinese Pharmaceutical Society in February issued "New Coronacy Infection: Hospital Pharmacological Guidance and Prevention strategy expert consensus" (first edition) specifically discussed adverse drug reactions and reuse, remindpharmacists should pay attention to the adverse reactions of all drugs;
    the monitoring of these adverse reactions is very important, systematically grasp these adverse reactions, can maximize the infection of patients to avoid secondary drug damage, for rational drug use, reduce patient mortality, improve the cure rate is very important.
    References: 1. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin, 2020; 2. A preliminary study on the siar toxicity of GS-5734 on male mice, 2020; 3. Effect of high vs Low Doses of chloroquine Diphosphate as adjunctive therapy for Patients Seied With Severe Sawith Sei-Sei-Ho 2 Infection: A Randomized Clinical Trial, 2020; 4. Anti-epidemic medications: always pay attention to adverse drug reactions, pharmaceutical guide, 2020; 5. Analysis of adverse drug reactions of new co-drug drugs for the treatment of new coronavirus pneumonia, Chinese pharmaceutical industry, 2020.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.